Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Teneligliptin

A DPP-4 inhibitor (gliptin) for type 2 diabetes, developed in Japan and launched there in 2012; it has also been approved in Korea, India and Argentina. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It has a J-shaped structure with five rings, described as an anchor-lock domain: a shape that hooks firmly onto the DPP-4 enzyme and blocks it strongly.

TeneligliptinGo to the active ingredient →
TeneligliptinActive ingredientTeneligliptinCat. No. P-T049-001CAS 760937-92-6

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.